Elbasvir & Grazoprevir

Pediatric

FDA APPROVAL DATE: 01/28/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Atazanavir, Atorvastatin, Bosentan, Carbamazepine, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Cyclosporine, Darunavir, Efavirenz, Fluvastatin, Ketoconazole, Lopinavir, Lovastatin, Modafinil, Moderate CYP3A inducers, Nafcillin, OATP1B1/3 inhibitors, Phenytoin, Rifampin, Rosuvastatin, Saquinavir, Simvastatin, Strong CYP3A inducers, Tacrolimus, Tipranavir

PREGNANCY CATEGORY: N/A
No available data; contra-indicated in pregnant women and in men with pregnant partners when administered with ribavirin

Contra-indicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C).

Our database has 23 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
RESPIRATORY
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of elbasvir & grazoprevir in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 03/01/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric